Biogen and Eisai submit Alzheimer's drug for European approval
Shortly after the US health authority gave its regulatory nod for the Alzheimer’s treatment, the pharmaceutical partnership seeks access to more markets for lecanemab.
by albert rønning-andersson, translated by daniel pedersen
Pharmaceutical partners Eisai and Biogen have submitted lecanemab, an Alzheimer’s treatment, for approval in Europe, a press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
